11 results match your criteria: "University Cancer Center Hamburg (Hubertus Wald Tumorzentrum)[Affiliation]"

Article Synopsis
  • - The study investigates the role of soluble CD27 (sCD27) and its potential as a biomarker to predict patient responses to immune checkpoint inhibitors (ICIs) in cancer therapy, as many patients do not achieve lasting results with current treatments.
  • - Researchers assessed serum and plasma levels of sCD27 across three patient cohorts (totaling 187 individuals) receiving ICI therapy, utilizing immunoassays and investigating both circulating and extracellular vesicle-bound forms of CD27.
  • - Results showed that lower levels of sCD27 in patients treated with ICIs were associated with longer progression-free survival and overall survival, suggesting that sCD27 could serve as a valuable predictive biomarker for the effectiveness of ICI treatments.
View Article and Find Full Text PDF

. In radiation oncology, experiments are often carried out using mice as a model forresearch studies. Due to recent technological advances in the development of high-precision small-animal irradiation facilities, the importance of quality assurance for both dosimetry and imaging is increasing.

View Article and Find Full Text PDF

Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays.

Cancer Lett

November 2020

Department of Radiotherapy and Radiation Oncology, University Cancer Center Hamburg - Hubertus Wald Tumorzentrum, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

Trifluridine/tipiracil (FTD/TPI; marketed as Lonsurf®) has shown clinically relevant activity after fluoropyrimidine failure in colorectal cancer and may thus be of increased efficacy compared with current standard capecitabine chemoradiation. Here we investigated the colorectal cancer cell lines HT29, HCT116, SW48 and Caco-2 to provide a preclinical rationale for FTD/TPI-based chemoradiation treatment. All lines incorporated similar amounts of FTD, irrespective of treatment concentration and duration, then arrested in S phase, showed persistent γH2AX induction and eventually underwent endoreplication, resulting in polyploidy.

View Article and Find Full Text PDF

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.

Cancer Immunol Immunother

November 2014

Department of Internal Medicine II, Oncology/Hematology/Bone Marrow Transplantation with the Section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Background: Multiple myeloma (MM) is the malignancy with the most frequent expression of the highly immunogenic cancer-testis antigens (CTA), and we have performed the first analysis of longitudinal expression, immunological properties, and fine specificity of CTA-specific antibody responses in MM.

Methods: Frequency and characteristics of antibody responses against cancer-testis antigens MAGE-A3, NY-ESO-1, PRAME, and SSX-2 were analyzed using peripheral blood (N = 1094) and bone marrow (N = 200) plasma samples from 194 MM patients.

Results: We found that antibody responses against CTA were surprisingly rare, only 2.

View Article and Find Full Text PDF

Acute psychological stress has primarily been investigated regarding its effects on conventional lymphocytes such as natural killer (NK) cells and CD4(+) and CD8(+) T cells. However, it might be important to focus on more "specialized" lymphocyte subsets, playing a role, for instance, in allergic conditions and autoimmunity, to identify links between stress, the immune system and somatic diseases. Using flow cytometry we determined frequencies of circulating T helper (Th)1-type (CD226(+)) and Th2-type (CRTH2(+)) T cells, γδ T cells, conventional CD56(+) natural killer T (NKT) cells and invariant NKT cells (iNKT) in healthy young males (N = 31; median age 26 years) undergoing a laboratory computer-based stressor lasting 12 min.

View Article and Find Full Text PDF

Role of interleukin 16 in multiple myeloma.

J Natl Cancer Inst

July 2012

Department of Medicine II, Oncology/Hematology/Stem Cell Transplantation, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg, Germany.

Background: Multiple myeloma is a malignancy characterized by the expansion of a plasma cell clone that localizes to the human bone marrow. Myeloma cells and bone marrow stromal cells produce soluble factors that promote the survival and progression of multiple myeloma. Interleukin 16 (IL-16) is involved in regulating the migration and proliferation of normal leukocytes.

View Article and Find Full Text PDF

Background: To date, multiple myeloma remains an incurable malignancy due to the persistence of minimal residual disease in the bone marrow. In this setting, monoclonal antibodies against myeloma-specific cell surface antigens represent a promising therapeutic approach, which is however hampered by a lack of appropriate target structures expressed across all pathogenic myeloma cell populations. We, therefore, investigated functionally relevant immunoreceptors specifically associated with myeloma cells as well as their clonogenic precursors.

View Article and Find Full Text PDF

Prognostic and diagnostic value of spontaneous tumor-related antibodies.

Clin Dev Immunol

April 2011

Department of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

There is an urgent need for earlier diagnosis of malignancies and more stringent monitoring of relapses after antitumor therapy. In addition, new prognostic markers are needed for risk stratification and design of individualized cancer therapies. New diagnostic and prognostic parameters should overcome the impairments of current standards in a cost-effective manner.

View Article and Find Full Text PDF

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

Bone Marrow Transplant

August 2011

1] Department of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, Department of Internal Medicine II, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhances the success of the CD34+ cell harvest, even in cases where prior mobilization attempts have failed.

View Article and Find Full Text PDF

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.

Exp Hematol

October 2010

Department of Internal Medicine II (Oncology/Hematology/Stem Cell Transplantation), University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Objective: The interaction of multiple myeloma (MM) with its bone marrow (BM) microenvironment is important for the homing pattern, survival, and proliferation of malignant plasma cells. We aimed at answering the question which cytokines, chemokines, and growth factors are typically found in the BM of untreated MM patients as well as in MM patients after allogeneic stem cell transplantation (alloSCT).

Materials And Methods: We determined the concentrations of 34 cytokines/chemokines in the supernatants of 10 myeloma cell lines, as well as in the plasma derived from BM and peripheral blood samples of 10 newly diagnosed MM patients, 20 MM patients who had received allogeneic stem cell transplantation (alloSCT), and 20 healthy donors.

View Article and Find Full Text PDF

Autoantibodies against tumor-related antigens: incidence and biologic significance.

Hum Immunol

July 2010

Department of Oncology, Hematology, Stem Cell Transplantation with the Section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

In the last two decades, tumors have been found to evoke antigen-specific immune responses. However, the biologic role of spontaneous tumor-specific T-cell and antibody responses are still a matter of controversy. Paradoxically, cancer-related immunity has been suggested to promote tumor growth, to effectively suppress tumor progression, or to simply represent a clinically irrelevant epiphenomenon.

View Article and Find Full Text PDF